GRENOBLE, France, July 7, 2015 /PRNewswire/ -- ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer (JITC) showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR® assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma. Results from the study, conducted at Memorial Sloan Kettering Cancer Center, were first presented at the SITC 2014 Annual Meeting.
Study results suggest that ImmunTraCkeR® may ultimately be used as a companion diagnostic for immune checkpoint agents, to determine eligibility to the treatment.
"We are delighted to have been selected by the JITC editorial board for publication. ImmunID's mission is to add precision to the immuno-oncology revolution by personalizing immunotherapy. A large multicenter study is currently underway (Predict-ID Melanoma, France) with the aim to validate prediction capabilities of ImmunTraCkeR® for response to immune checkpoint inhibitors. This is an area of high unmet medical need and could be game-changing for patients," said Bernhard Sixt, ImmunID's Chairman and Chief Executive Officer.
The electronic version of the JITC article can be found online at: http://www.immunotherapyofcancer.org/content/3/1/23
ImmunTraCkeR® is a proprietary CE-marked immune molecular diagnostics assay, which evaluates a patient's immune status in the blood based on combinatorial T cell diversity. Unlike most companion diagnostics tests, ImmunTraCkeR® is patient-specific rather than drug- or disease-specific, as it approaches the disease from the patient's own immune system perspective. ImmunTraCkeR® provides information on the patient's complex immune profile to evaluate clinical benefit or risk under treatment with immunotherapies. ImmunTraCkeR® may ultimately be used as immune companion diagnostics and answer the urgent medical need for efficient patient stratification tools in melanoma and other solid cancers.
ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIG® evaluate a patient immune status based on T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostics for all immunotherapies and is setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostics for new immunotherapies and to widen clinical utility of its products. The company is ISO 9001 certified and runs an ISO 13485, CAP-accredited facility in the MINATEC high-tech campus in Grenoble, France.
Chairman and CEO
Phone: +33 438 785 770
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-advancing-the-clinical-utility-of-immunids-immuntracker-for-prediction-of-response-to-immune-checkpoint-inhibitors-published-in-the-journal-for-immunotherapy-of-cancer-300109329.html